Drug profile · INN
olanzapine pamoate
ZYPREXA RELPREVV
olanzapine pamoate (ZYPREXA RELPREVV) is a serotonin 2a (5-ht2a) receptor antagonist. Route of administration: intramuscular. Current US regulatory status: approved.
Drug details — olanzapine pamoate
- US status
- approved
- Class
- —
- Route
- INTRAMUSCULAR
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
olanzapine pamoate (ZYPREXA RELPREVV) is a serotonin 2a (5-ht2a) receptor antagonist. Route of administration: intramuscular. Current US regulatory status: approved.
Key facts
Mechanism of action
Serotonin 2a (5-HT2a) receptor antagonist
Primary target: D2-like dopamine receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is olanzapine pamoate?
olanzapine pamoate (ZYPREXA RELPREVV) is a serotonin 2a (5-ht2a) receptor antagonist. Route of administration: intramuscular. Current US regulatory status: approved.
What is the brand name for olanzapine pamoate?
ZYPREXA RELPREVV is a marketed brand name for olanzapine pamoate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of olanzapine pamoate?
olanzapine pamoate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.